Normando Iznaga-Escobar

798 total citations
25 papers, 622 citations indexed

About

Normando Iznaga-Escobar is a scholar working on Radiology, Nuclear Medicine and Imaging, Oncology and Pathology and Forensic Medicine. According to data from OpenAlex, Normando Iznaga-Escobar has authored 25 papers receiving a total of 622 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Radiology, Nuclear Medicine and Imaging, 11 papers in Oncology and 5 papers in Pathology and Forensic Medicine. Recurrent topics in Normando Iznaga-Escobar's work include Radiopharmaceutical Chemistry and Applications (18 papers), Monoclonal and Polyclonal Antibodies Research (14 papers) and HER2/EGFR in Cancer Research (10 papers). Normando Iznaga-Escobar is often cited by papers focused on Radiopharmaceutical Chemistry and Applications (18 papers), Monoclonal and Polyclonal Antibodies Research (14 papers) and HER2/EGFR in Cancer Research (10 papers). Normando Iznaga-Escobar collaborates with scholars based in Cuba, India and Uruguay. Normando Iznaga-Escobar's co-authors include Mayra Ramos, Rolando Pérez, René Figueredo, Eduardo Fernández, Olga Torres, Tania Crombet, Agustín Lage, I. Leonard, James Koropatnick and Marta Osorio and has published in prestigious journals such as Journal of Clinical Oncology, International Immunopharmacology and Journal of Neuro-Oncology.

In The Last Decade

Normando Iznaga-Escobar

25 papers receiving 609 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Normando Iznaga-Escobar Cuba 14 327 301 196 161 70 25 622
Giselle Saurez Cuba 8 203 0.6× 138 0.5× 80 0.4× 223 1.4× 51 0.7× 11 459
Stefano Vagge Italy 13 114 0.3× 161 0.5× 180 0.9× 85 0.5× 72 1.0× 39 472
Masako Uno Japan 12 148 0.5× 130 0.4× 87 0.4× 180 1.1× 45 0.6× 38 528
Pontus K.E. Börjesson Netherlands 8 189 0.6× 330 1.1× 118 0.6× 125 0.8× 10 0.1× 9 522
Yvonne W. S. Jauw Netherlands 11 247 0.8× 596 2.0× 195 1.0× 93 0.6× 27 0.4× 24 742
H.A. Burris United States 13 496 1.5× 111 0.4× 213 1.1× 316 2.0× 47 0.7× 63 679
Lara Buchmiller United States 7 361 1.1× 69 0.2× 281 1.4× 181 1.1× 28 0.4× 7 600
H. A. Burris United States 17 534 1.6× 119 0.4× 218 1.1× 271 1.7× 81 1.2× 57 770
Cyrus Amir United States 11 254 0.8× 91 0.3× 184 0.9× 197 1.2× 101 1.4× 14 652
Mary‐Keara Boss United States 11 161 0.5× 98 0.3× 205 1.0× 142 0.9× 24 0.3× 41 616

Countries citing papers authored by Normando Iznaga-Escobar

Since Specialization
Citations

This map shows the geographic impact of Normando Iznaga-Escobar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Normando Iznaga-Escobar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Normando Iznaga-Escobar more than expected).

Fields of papers citing papers by Normando Iznaga-Escobar

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Normando Iznaga-Escobar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Normando Iznaga-Escobar. The network helps show where Normando Iznaga-Escobar may publish in the future.

Co-authorship network of co-authors of Normando Iznaga-Escobar

This figure shows the co-authorship network connecting the top 25 collaborators of Normando Iznaga-Escobar. A scholar is included among the top collaborators of Normando Iznaga-Escobar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Normando Iznaga-Escobar. Normando Iznaga-Escobar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Fleischhack, Gudrun, Maura Massimino, Monika Warmuth‐Metz, et al.. (2019). Nimotuzumab and radiotherapy for treatment of newly diagnosed diffuse intrinsic pontine glioma (DIPG): a phase III clinical study. Journal of Neuro-Oncology. 143(1). 107–113. 30 indexed citations
2.
García, María Fernanda, Marcelo Fernández, Normando Iznaga-Escobar, et al.. (2016). Fab(nimotuzumab)-HYNIC-99mTc: Antibody Fragmentation for Molecular Imaging Agents. Anti-Cancer Agents in Medicinal Chemistry. 16(9). 1184–1189. 4 indexed citations
3.
Zhang, Xiuli, Marcelo Fernández, Normando Iznaga-Escobar, et al.. (2012). A Potencial Theranostic Agent for EGF-R Expression Tumors: 177Lu- DOTA-Nimotuzumab. Current Radiopharmaceuticals. 5(4). 318–324. 7 indexed citations
4.
5.
Figueredo, René, et al.. (2005). Local and systemic toxicity of h-R3, an anti-epidermal growth factor receptor monoclonal antibody, labeled with 188osmiun after the intracerebral administration in rats. Experimental and Toxicologic Pathology. 56(4-5). 313–319. 4 indexed citations
6.
Torres, Leonel, et al.. (2005). Phase I/II clinical trial of the humanized anti-EGF-r monoclonal antibody h-R3 labelled with 99mTc in patients with tumour of epithelial origin. Nuclear Medicine Communications. 26(12). 1049–1057. 25 indexed citations
7.
Iznaga-Escobar, Normando, et al.. (2004). Factors affecting pharmacokinetics of monoclonal antibodies: Areview article.. Methods and Findings in Experimental and Clinical Pharmacology. 26(2). 123–123. 14 indexed citations
8.
Iznaga-Escobar, Normando, et al.. (2004). 99mTc-labeled murine ior C5 monoclonal antibody in colorectalcarcinoma patients: Pharmacokinetics, biodistribution, absorbedradiation doses to normal organs and tissues and tumor localization. Methods and Findings in Experimental and Clinical Pharmacology. 26(9). 687–687. 6 indexed citations
9.
Tejuca, Mayra, Isabel Dı́az, René Figueredo, et al.. (2004). Construction of an immunotoxin with the pore forming protein StI and ior C5, a monoclonal antibody against a colon cancer cell line. International Immunopharmacology. 4(6). 731–744. 36 indexed citations
10.
Crombet, Tania, Marta Osorio, Teresa Cruz, et al.. (2004). Use of the Humanized Anti-Epidermal Growth Factor Receptor Monoclonal Antibody h-R3 in Combination With Radiotherapy in the Treatment of Locally Advanced Head and Neck Cancer Patients. Journal of Clinical Oncology. 22(9). 1646–1654. 237 indexed citations
11.
Iznaga-Escobar, Normando, et al.. (2003). 188Re-labeled antiepidermal growth factor receptor humanizedmonoclonal antibody h-R3: Labeling conditions, in vitro and in vivostability. Methods and Findings in Experimental and Clinical Pharmacology. 25(9). 703–703. 7 indexed citations
12.
Vallis, Katherine A., Raymond M. Reilly, Amit M. Oza, et al.. (2002). A phase I study of 99mTc-hR3 (DiaCIM®), a humanized immunoconjugate directed towards the epidermal growth factor receptor. Nuclear Medicine Communications. 23(12). 1155–1164. 25 indexed citations
13.
Mishra, Anil K., Normando Iznaga-Escobar, René Figueredo, et al.. (2002). Preparation and comparative evaluation of 99mTc-labeled2-iminothiolane modified antibodies and CITC-DTPA immunoconjugatesof anti-EGF-receptor antibodies. Methods and Findings in Experimental and Clinical Pharmacology. 24(10). 653–653. 13 indexed citations
14.
15.
Morales, Alejo A., et al.. (2000). Humanized versus murine anti-human epidermal growth factor receptor monoclonal antibodies for immunoscintigraphic studies. Nuclear Medicine and Biology. 27(2). 199–206. 12 indexed citations
16.
17.
Morales, Alejo A., et al.. (1999). Freeze-dried formulation for direct 99mTc-labeling ior-egf/r3 MAb: additives, biodistribution, and stability. Nuclear Medicine and Biology. 26(6). 717–723. 7 indexed citations
18.
Ramos, Mayra, Nelson Rodríguez, Normando Iznaga-Escobar, et al.. (1999). 99mTc-labeled antihuman epidermal growth factor receptor antibody in patients with tumors of epithelial origin: Part III. Clinical trials safety and diagnostic efficacy.. PubMed. 40(5). 768–75. 43 indexed citations
19.
Iznaga-Escobar, Normando. (1998). 188Re-Direct Labeling of Monoclonal Antibodies for Radioimmunotherapy of Solid Tumors: Biodistribution, Normal Organ Dosimetry, and Toxicology. Nuclear Medicine and Biology. 25(5). 441–447. 35 indexed citations
20.
Iznaga-Escobar, Normando, et al.. (1998). Technetium-99m-antiepidermal growth factor-receptor antibody in patients with tumors of epithelial origin: part II. Pharmacokinetics and clearances.. PubMed. 39(11). 1918–27. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Giselle Saurez Breakdown of academic impact, for papers by Stefano Vagge Breakdown of academic impact, for papers by Masako Uno Breakdown of academic impact, for papers by Pontus K.E. Börjesson Breakdown of academic impact, for papers by Yvonne W. S. Jauw Breakdown of academic impact, for papers by H.A. Burris Breakdown of academic impact, for papers by Lara Buchmiller Breakdown of academic impact, for papers by H. A. Burris Breakdown of academic impact, for papers by Cyrus Amir Breakdown of academic impact, for papers by Mary‐Keara Boss
Rankless by CCL
2026